Medical devices: urgent need for reform

Perspective / 25 January 2019

Photo: iStock

Recent investigations into faulty medical device regulation have highlighted the need to broaden the scope of pharmacovigilance, to include more than just medications.

The International Consortium of Investigative Journalists (ICIJ) started releasing the Implant Files in late 2018. Their collection of investigative articles, researched by over 250 journalists worldwide, digs deep into the regulation of medical devices. Numerous examples of patient harm from across the globe paint a bleak picture of insufficient testing and regulation of medical devices, and of regulatory processes that are less than transparent and lend themselves to conflicts of interest. The category of devices includes anything that is placed inside the human body: breast implants, vaginal mesh, pacemakers, artificial hips, stents, heart valves, contraceptive devices, and so on.

Data from the US suggest that, in the last decade, around 80,000 deaths and 1.7 million injuries were possibly attributable to devices; in the European Union, with ‘light-touch’ regulation, there has been a steep rise in incident reports in recent years. The ICIJ summarises its findings as follows: “Patients around the world have become unwitting test subjects for new medical technology. Often following the trusted advice of their doctors, they have been injured, maimed and killed by poorly-tested implants.”

At Uppsala Monitoring Centre, we believe that transparency in all matters relating to the safety of medicines and devices is an essential element of ethical regulatory practice. Health professionals, patients and society at large have a right to full information about all matters that affect their health.

In their 2016 article “Pharmacovigilance is …vigilance”, Ralph Edwards and Rachida Soulaymani Bencheikh argue that medical devices are the proper concern of pharmacovigilance as much as medications; that the growing focus on individual patient welfare, alongside epidemiological perspectives, demands the adaptation of traditional methods and the development of new expertise. Many countries in the world rely on approvals in the US or Europe and have no local system for reporting device failures.

The ICIJ report makes it clear that the same stringent regulatory principles for medicines should also apply to medical devices and that there is an urgent need for reform.

Read more:

Uppsala Monitoring Centre @UMCGlobalSafety
World Health Organization (WHO) Collaborating Centre for International Drug Monitoring

You may also like

Start small, but think big: Trials and triumphs of #MedSafetyWeek campaigners

As we prepare for the eighth rendition of the #MedSafetyWeek campaign, we talk to some seasoned campaigners on how to run a successful campaign.

Perspective / 30 October 2023

What’s trending in pharmacovigilance? New podcast episode

In this festive edition of Drug Safety Matters, we wrap up the year that was and look ahead to the year that will be – with a little help from one of our friends.

Perspective / 21 December 2023

Risk Communications in Healthcare – Bridging the Gap

Effective risk communication is a mainstay of successful pharmacovigilance, yet examples of poor risk mitigation abound. Where are we failing, and what can be done about it?

Perspective / 20 November 2023

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more